SCHEMBL3337836

SCHEMBL3337836

CC(C)CNC(=O)c1ccc(-c2ccc3nc(N)nc(OC(C)C)c3c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
HDAC4 P56524 1/20 0.41
HPGD P15428 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
DYRK1A Q13627 2/20 0.41
GSK3B P49841 1/20 0.41
F2 P00734 2/20 0.41
F10 P00742 2/20 0.41
F7 P08709 2/20 0.41
F3 P13726 2/20 0.41
KMT2A Q03164 2/20 0.40
GAA P10253 2/20 0.40
HSD17B10 Q99714 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
MLYCD O95822 1/20 0.39
NAMPT P43490 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337998 0.89 HPGD (0.51) KDM4EHDAC4HPGDNPSR1DYRK1A
SCHEMBL3336054 0.88 HPGD (0.42) KDM4EHDAC4HPGDNPSR1DYRK1A
SCHEMBL3336495 0.87 MKNK1 (0.42) HPGDNPSR1KMT2AMEN1ALDH1A1
SCHEMBL3336523 0.87 IP6K1 (0.47) HDAC4NPSR1GAAALDH1A1HDAC1
SCHEMBL3340852 0.87 NAMPT (0.44) KDM4EHPGDKMT2AGAAHSD17B10
SCHEMBL3336068 0.87 TP53 (0.49) HPGDDYRK1AGSK3BNPC1RAB9A
SCHEMBL3333686 0.86 BRAF (0.47) HDAC4HPGDNAMPTALDH1A1HDAC1
SCHEMBL3338723 0.86 HDAC4 (0.41) KDM4EHDAC4HPGDNPSR1DYRK1A
SCHEMBL3336047 0.86 RXRA (0.38) HDAC1
SCHEMBL3336913 0.84 MAPK14 (0.45) KDM4EHDAC4HPGDNPSR1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 KDM4E 3125/4885HDAC4 1425/4885HPGD 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.